CagriSema

(Cagrilintide + Semaglutide) CagriSema is a co-formulated combination therapy containing 2.4 mg each of Cagrilintide (a long-acting amylin analog) and Semaglutide (a GLP-1 receptor agonist), administered as a single weekly subcutaneous injection. This dualhormone approach targets obesity and type 2 diabetes through complementary mechanisms. Cagrilintide functions as an amylin and calcitonin receptor agonist, with a half-life of 184±7.4 hours, enhancing satiety, slowing gastric emptying, and reducing postprandial glucagon secretion through brainstem pathways. Semaglutide is a GLP-1 receptor agonist with a half-life of 158 hours, stimulating glucosedependent insulin secretion, glucagon suppression, and improving gastric motility via hypothalamic appetite regulation. Together, CagriSema offers dual appetite suppression and comprehensive metabolic control, achieving superior weight loss and glycemic management, with clinical outcomes comparable to bariatric surgery.